Inner Mongolia Furui Medical Science Co., Ltd. (SHE:300049)
China
· Delayed Price · Currency is CNY 55.71
-1.28 (-2.25%)
Mar 9, 2026, 3:04 PM CST
SHE:300049 Revenue
Inner Mongolia Furui Medical Science had revenue of 387.63M CNY in the quarter ending September 30, 2025, with 14.94% growth. This brings the company's revenue in the last twelve months to 1.47B, up 10.83% year-over-year. In the year 2024, Inner Mongolia Furui Medical Science had annual revenue of 1.35B with 16.93% growth.
Revenue (ttm)
1.47B
Revenue Growth
+10.83%
P/S Ratio
10.04
Revenue / Employee
1.70M
Employees
867
Market Cap
14.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.35B | 195.28M | 16.93% |
| Dec 31, 2023 | 1.15B | 144.97M | 14.37% |
| Jan 1, 2023 | 1.01B | 110.28M | 12.27% |
| Jan 1, 2022 | 898.48M | 90.95M | 11.26% |
| Dec 31, 2020 | 807.53M | -24.21M | -2.91% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| Anhui Anke Biotechnology (Group) | 2.58B |
| Vcanbio Cell & Gene Engineering Corp., | 1.47B |
| Jinyu Bio-technology | 1.33B |
| Mabwell (Shanghai) Bioscience | 662.52M |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| BrightGene Bio-Medical Technology | 1.22B |
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 16.62B |